Q3 2021 13F Holders as of 30 Sep 2021
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
1.08B
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
31.9M
-
Shares change
-
+4.62M
-
Total reported value, excl. options
-
$311M
-
Value change
-
+$41.9M
-
Put/Call ratio
-
4.1
-
Number of buys
-
67
-
Number of sells
-
-38
-
Price
-
$9.74
Significant Holders of ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) as of Q3 2021
141 filings reported holding IBRX - ImmunityBio, Inc. - Common Stock, par value $0.0001 per share as of Q3 2021.
ImmunityBio, Inc. - Common Stock, par value $0.0001 per share (IBRX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 31.9M shares
of 1.08B outstanding shares and own 2.96% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (7.03M shares), BlackRock Inc. (5.55M shares), STATE STREET CORP (5.32M shares), GEODE CAPITAL MANAGEMENT, LLC (1.52M shares), NORTHERN TRUST CORP (1.26M shares), JPMORGAN CHASE & CO (1.2M shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (885K shares), ALLEN HOLDING INC /NY (688K shares), MORGAN STANLEY (498K shares), and CHARLES SCHWAB INVESTMENT MANAGEMENT INC (458K shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.